In plain English: Put the Station in urgent care clinics and pharmacies and earn money from the test supplies it uses. Start in our own laboratory to prove it works, and raise money in stages that are released only when the data passes.

1. Executive summary

What we are building. Thimble Dx makes a counter-top blood-testing station for pharmacies and urgent care clinics, backed by a central microsample laboratory. The design target: about 40 assays plus a 19-parameter complete blood count from roughly 300 microliters of capillary blood, with all in-store results in about 15 minutes and specialty tests from the same visit back the same day.

Why this can work when Theranos could not. Theranos tried to run 200-plus tests on one proprietary engine from one undifferentiated drop, then lied when it could not. Every piece Thimble needs already exists and has been cleared or CE-marked by someone: centrifugal chemistry discs (Abaxis, 1995), imaging hematology from a fingerstick (Sight OLO 2019, PixCell HemoScreen 2023), fluorescence immunoassay readers (Boditech, about 60,000 installed), single-use electrochemistry (i-STAT, 1992), cleared capillary collection (Tasso 2022, BD MiniDraw 2023). Truvian proved in 2025-2026 that FDA will clear a multi-modal benchtop; Babson proved that pharmacy staff can collect fingertip blood for a 68-test menu. Thimble integrates proven engines, splits the sample at collection, measures interference on every sample, and refuses to report what it cannot stand behind.

The gap. Our scorecard of 69 companies and products found every part of the 2013 vision achieved by someone and nobody with all six parts. Truvian is venous-only and launching with Siemens Healthineers. Babson sends drops to a central lab, so results are not ready during the visit. Sight Diagnostics, maker of the best fingerstick CBC ever cleared in the US, laid off its last employees in April 2026.

How we make money. Stations are placed on reagent rental. Sites buy consumables (about $20 per patient on average) and software ($149 a month per Station). The hub lab bills about $48 per requisition on average, from cash panels and insured orders.

The plan. Bench prototypes in 2027; our own CAP-accredited lab running the Station as laboratory-developed tests, with partner pharmacies collecting, from 2028; first FDA clearances in 2030; CLIA waivers for the waivable modules in 2031; 400 Stations in the field by the end of 2031 and 1,600 by the end of 2033, when the base case turns EBITDA-positive.

The ask. $0.75 million pre-seed now, then $10 million seed (2027), $40 million Series A (2028) and $80 million Series B (2030): $130.75 million in total. For comparison, Truvian raised roughly $206 to $294 million before its first clearances, and LumiraDx raised more than $779 million before it collapsed.

The integrity commitment. A ten-point honesty charter, written into the bylaws and every investor agreement, answers each specific Theranos failure: publish before promoting, a named and empowered lab director, an independent quality committee, whistleblower protection, no demo modes, capillary claims only from capillary data, and regulatory status printed on every report.

2. Mission

Make routine blood testing as close as the nearest pharmacy, with results while you wait, at posted prices, and with every claim backed by public data.

The full honesty charter is in the regulatory document. It is not marketing; it is the product. In 2026 every article about a fingerstick blood test mentions Theranos. A company that publishes its method comparisons before launch, names its laboratory director, and suppresses results it cannot validate will be trusted because the field is scarred.

3. The problem

• Lab testing drives medicine but sits behind a separate trip. The US runs about 14 billion laboratory tests a year in about 266,000 CLIA-certified laboratories, and lab results inform more than 75 percent of clinical decisions. For most outpatients, getting blood drawn still means a separate visit to a patient service center, a venipuncture, and results that arrive after the patient has gone home.
• Phlebotomy is a bottleneck. The US had about 143,900 phlebotomist jobs in 2025, with about 18,000 openings a year to fill.
• Point-of-care testing is an instrument zoo. A clinic that wants results during the visit buys one analyzer for HbA1c, another for lipids, another for a CBC, another for CRP, another for chemistry, each with its own consumables, calibration and QC. A HemoScreen CBC analyzer alone lists at $16,250.
• Pharmacies need new revenue and have new authority. Walgreens booked a $3.0 billion impairment on VillageMD in fiscal 2025 and is closing stores; Walmart closed all 51 Walmart Health centers in 2024. Meanwhile pharmacies holding CLIA waivers grew 173 percent from 2015 to 2023, 48 states allow pharmacist point-of-care testing, and test-and-treat laws keep expanding (Iowa 2024, North Carolina 2025, Rhode Island 2026).

4. Why now

1. Every engine is proven and much of the core prior art has expired. Abaxis's discs date to the 1990s and i-STAT's cartridge to 1992; early Theranos patents such as US 7,291,497 are listed as expired.
2. Capillary collection is cleared. Tasso+ (510(k) 2022), YourBio TAP Micro Select (2023) and BD MiniDraw (2023, for pharmacies and other non-traditional sites).
3. FDA clears multi-modal benchtops. Truvian's TruVerus: 26 cleared assays between December 2025 and January 2026, including the first CBC cleared from a lithium-heparin sample.
4. Imaging hematology works. Fingerstick CBCs are cleared (OLO, HemoScreen); Athelas's AI white-cell count was cleared for pharmacies in February 2026.
5. The laboratory-developed test path reopened. A federal court vacated FDA's LDT rule on March 31, 2025 and FDA did not appeal, so a CAP-accredited lab can validate and run the Station on patients before FDA clearance, generating revenue and capillary evidence.
6. Consumers now pay cash for lab tests. Function Health sells 160-plus tests for $365 a year and raised $450 million in July 2026; Babson posts a CBC at $25.
7. The best fingerstick CBC company just disappeared. Sight Diagnostics' shutdown in April 2026 leaves cleared-technology talent and an unserved market.

5. The product

In-store menu (version 1): a 19-parameter CBC and HbA1c; sodium, potassium, chloride, total CO2, glucose, BUN, creatinine, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin, cholesterol, HDL, triglycerides (with calculated LDL, non-HDL and eGFR); GGT, magnesium, phosphorus, uric acid, creatine kinase, amylase, iron, direct bilirubin; TSH, free T4, hs-CRP, ferritin, vitamin D, PSA, hCG; and for urgent care troponin I, NT-proBNP, D-dimer, procalcitonin, CRP, ionized calcium and lactate.

At the hub: everything that needs a central analyzer or more sample, such as ApoB, lipoprotein(a), sex hormones, cortisol, B12 and folate, PTH, serology, celiac and autoimmune panels, and drug levels.

6. Market

The serviceable estimate excludes physician offices (122,634 held waived certificates in 2015), employer clinics, senior living and international markets, and it excludes the hub lab's own revenue.

7. Customers and go-to-market

Beachhead. One metro first, chosen on direct-access testing law, pharmacist scope, whether the state separately licenses lab personnel, the density of independent pharmacies and urgent cares, and competition. Three candidates for the founder's decision:

Sales motion. Enterprise sales to urgent care groups (concentrated ownership makes deals efficient); pharmacies through independent pharmacy networks and wholesaler programs; health systems through laboratory outreach. Partner rule: no single partner above 25 percent of sites. Theranos depended on Walgreens and Safeway; Walmart Health and VillageMD show what happens to services that depend on one retailer's economics.

8. Business model and pricing

Placement. Reagent rental: the Station is placed with no upfront cost against a minimum consumables commitment of $1,200 a month (about 3 patients a day), or sold outright at $14,000.

Suggested cash menu for pharmacies (the site sets its own prices):

For reference, Babson's posted prices are $25 for a CBC, $19 for a comprehensive metabolic panel, $19 for an HbA1c and $15 for a hepatic panel; Function Health charges $365 a year for 160-plus tests at Quest.